49 search results for: coexisting diseases
Beyond the Skin: Cumulative Disease Burden in Children With Atopic Dermatitis
Dr. Lara Wine Lee discusses the concept of cumulative life course impairment in AD, focusing on non-atopic comorbidities like vertical growth deficits and mental health impairment and how these might be preventable with early intervention at PeDRA 2025.
Cumulative Impact of Uncontrolled Atopic Dermatitis: Skin Inflammation as the Tip of the Iceberg
Prof Jean-David Bouaziz describes the multifaceted burden of atopic dermatitis, beyond what can be seen on the skin, at EADV 2025.
Atopic Dermatitis and Prurigo Nodularis: Clarifying Perspectives and Common Misconceptions
This is the ADVENT-branded video of the IDEF presentation that was presented during the 1-hour webinar on December 1st featuring both Dr. Sarina Elmariah and Dr. Jason Hawkes.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
Professors Bouaziz and Paller discuss the clinical burden and potential biomarkers of subclinical control in AD, at EADV 2025.
The Growing Burden: Cumulative Disease Impact and Comorbidities in Pediatric AD
Dr. Yu and Dr. Wine Lee discuss the clinical presentation and burden of atopic dermatitis, the role of type 2 inflammation in the development of atopic comorbidities, and the importance of early intervention in potentially preventing cumulative life course impairment in AD at PeDRA 2025.
Barrier Breakdown: The Role of Type 2 Inflammation in AD and Atopic Sensitization
Dr. Jeff Yu presents the clinical presentation of pediatric AD and highlights how type 2 inflammation contributes to symptoms and development of atopic comorbidities such as food allergy and asthma at PeDRA 2025
Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.
